Introduction
Heart failure (HF) is among the main causes of mortality and morbidity. Patients with HF following chronic ischemic heart diseases usually are presented with poor prognosis. Current treatment modalities are mostly palliative and are aimed at alleviating the symptoms and controlling the advancement of the disease. [1] [2] [3] [4] Final therapeutic option is organ transplantation, which is seriously impeded by donor shortage, donor matching and complication rising during and after cardiac transplantation procedure. 2, 5, 6 The operation is very risky and patients need to take immunosuppressive drugs for their whole life, although despite lifelong immunosuppressive therapy, there is a possibility for transplant rejection. [7] [8] [9] Therefore, search for new therapeutic options is a must for treating patients with HF. One of the recent approaches which stands a chance for being used for the treatment of the disease is cellular cardiomyoplasty, use of stem cells to repair regions of damaged or necrotic myocardium. 10 Cell-based approaches have shown promise in some studies for the treatment of acute and subacute myocardial ischemia. Mesenchymal stem cells (MSCs) have gained popularity for their use in myocardial regeneration. 11 According to the International Society for Cellular Therapy (ISCT) minimal criteria for defining the multipotent MSCs, these are plastic-adherent cells, expressing CD105, CD73 and CD90 markers and lacking the surface presentation of CD45, CD34, CD14 or CD11b, CD79a or CD19 and HLA-DR markers. Moreover, they have the capacity for in vitro differentiation to osteoblasts, adipocytes and chondroblasts. 12 These cells could be obtained from various sources in the body, and despite common features defined by the minimal criteria set of the ISCT, have some differences in their replicative capacity and therapeutic potential. One of these sources is the fetal membranes, including amniotic membrane. 13 The amniotic membrane and other fetal adnexa are regarded as wastes of childbirth and as a source of stem cells, they are specially interesting due to the availability without bearing comorbidity to the donor. 13 Recent studies have shown the promise of these cells in the treatment of acute and subacute myocardial ischemia and ameliorated HF in the rodent models of these disease. [13] [14] [15] However, it is not clearly defined if treatment with these cells may offer any benefits in patients suffering from chronic ischemic HF. Although the MSCs are shown to differentiate to cells with myocardial and endothelial features, doubts exist regarding their functionality, and even some studies have suggested that myocardial cells differentiated from MSCs lack the features of a viable cardiomyocyte with contractile function. Most of the studies suggest that MSCs are effective in acute myocardial ischemia due to their immunomodulatory properties as well as proangiogenic properties. Actually, during acute ischemia there are elevated oxidative stress and inflammatory response, which cause the cell death of the ischemic tissue. [16] [17] [18] [19] [20] [21] [22] [23] [24] These cells help improve tissue hemostasis through modulating the immune response and improving blood flow by angiogenesis induction and sparing the existing cardiomyocytes from apoptotic and necrotic cell death. 11, 13, 14, 25 Therefore, studying their applicability in chronic ischemic HF, where severe inflammatory response and myocardial cell death have led to tissue remodeling and tissue fibrosis, is required. In the current study, we hypothesized that MSC from human term amniotic membrane might differentiate into cardiomyocyte or endothelial-like cells and improve the myocardial function in the chronic ischemic HF rat model when administered surgically. The potential of these cells for homing in the myocardial tissue of the rat model of HF following surgical intramyocardial injection, altering cardiac function, regenerating fibrotic tissue, and their potential in vivo differentiation to the cardiomyocytes and endothelial-like cells are investigated.
Materials and Methods

Cell isolation and characterization
Cells were isolated and characterized as previously described. 25 Human placentas were obtained from healthy female donors during caesarean section with prior informed consent of the donors. After transfer to the laboratory in sterile phosphate-buffered saline (PBS) and antibiotics, the amniotic membrane was isolated from placenta and cut into small pieces. Cells were dissociated using collagenase type I (Gibco, Grand Island, USA) in a shaking incubator at 37°C for 1-2 hours. Then, cells were suspended in the low glucose DMEM culture medium (Sigma Aldrich, Gillingham, Wisconsin, USA) containing 10% FBS (Invitrogen, Camarillo, California, USA) and 1% of standard Penicillin-Streptomycin solution (10 000 units penicillin and 10 mg streptomycin/ml) (Gibco, Grand Island, USA). Then, cells were seeded into T75 flasks (Nunc, Roskilde, Denmark). The flasks were placed in an incubator at 37°C in 5% CO2 and 95% humidity. After three passages, cells were tested for the following cell surface markers: CD34-PE, CD44-FITC, CD45-FITC, CD73-PE, CD90-PE and CD105-FITC by flow cytometry technique (Partec 3, USA). Osteoblast and adipocyte differentiation capability of hAM-MSCs was tested in vitro as previously described. 
Lentivirus-green fluorescent protein (Lenti-GFP) transduction for tracking
Gene delivery to the hAMSCs was performed using a second generation lentiviral vector system. 27 pLV-IRES-GFP, a bicistronic lentiviral vector with an EF-1 alpha promoter was used for the transduction of the cells, their labeling with GFP and tracking of the transplanted cells in vivo using GFP fluorescent microscopy of the tissue sections. The process for preparation and viral transduction of the cells has been described elsewhere.
26
Animal experiments and hAMSCs administration Twenty-four male Wistar rats weighing between 250 to 350 g were provided by Laboratory Animal, Breeding and Husbandry Center, Iran University of Medical Sciences, Tehran, Iran. All animals were stored under standard conditions in cages at a controlled temperature (25°C), with daily exposure to a 20-hour light-dark cycle and free access to standard laboratory food and tap water. Animals were randomly allocated to three groups: Sham group received only chest opening without any extra manipulation; HF control group underwent left anterior descending artery (LAD) ligation and received PBS as the carrier 4 weeks later and HF+hAMSCs group, which underwent LAD ligation and received hAMSCs (passage 6, P6) as treatment four weeks later.
LAD ligation was performed using a 6-0 Prolene (Ethicon Inc., USA) suture as previously described.
Animals were anesthetized by intra-peritoneal administration of a mixture of 75 mg/kg ketamine and 5 mg/kg xylazine. Then, animals were orally intubated with a 16-gauge intravenous catheter and placed in the supine position on a warming pad with anal temperature control thermometer. Animals were ventilated with the room air using a modified infant ventilator (Sechrist Industries, USA) during operation. Electrocardio-graphic monitoring was applied for monitoring the vital signs. The heart was exposed via left thoracotomy by cutting the fourth and fifth ribs. The pericardial sac was opened, and LAD was ligated permanently. Pale discoloration of the left ventricular muscle was regarded as the confirmation of the successful ligation of the LAD. To stitch the muscle layer and skin incision, 4-0 Prolene and 2-0 silk suture were respectively used. At the end of surgery, erythromycin (10 mg/kg, SC), ketoprofen 10% (10 mg/kg IM.), and warm sterile saline (1-2 mL, SC) were injected, and the rats were left on the heating pad until they had recovered from anesthesia. After that, rats were extubated and removed from the ventilator. The dose of flunixin was repeated every 6 to 12 hours.
Cell administration was done four weeks following LAD ligation in four points around the ischemic area. 2×10 6 cells were suspended in 200 µL of PBS and were immediately injected into the myocardium of the left ventricle in the border zone of the ischemic area.
For assessing the myocardial function, rats underwent ketamine-xylazine anesthesia for echocardiographic examination of the heart. A Vivid 7 echocardiography machine (GE Healthcare Italia, Milano, Italy) equipped with 10 MHz phased array transducer was utilized for this purpose as previously described. 30 Ejection fraction(EF) and fractional shortening (FS) were acquired and calculated for each animal.
Tissue staining and immunohistochemistry
About 4 weeks after stem cell administration or serving as either sham or untreated control or vehicle, animals were sacrificed and their hearts were isolated and embedded in paraffin after fixation with 10% paraformaldehyde solution. Three sections (5 μm thick) were prepared with a 2000-μm interval from apex for trichrome staining or immunohistochemical analysis.
Masson's trichrome staining was performed on cardiac sections to estimate the total amount of damage and fibrosis of the myocardial tissue as previously described. 31 Immunohistochemistry was used to detect the expression of GFP, vascular-endothelial growth factor (VEGF) or cardiac troponin T in the myocardial tissue. For studying the endothelial-or cardiomyocyte differentiation of the introduced hAMSCs, tissue sections for double stained for the presence of GFP and either VEGF or troponin T. For this purpose, the tissue sections were incubated for 45 minutes at 37°C in a blocking solution (10% normal goat serum, 3% Triton X-100 in PBS) followed by incubation in a monoclonal anti-GFP (orb10709, Biorbyt, Cambridge, UK), anti-VEGF (orb11554, Biorbyt, Cambridge, UK) or anti-troponin T (orb182936, Biorbyt, Cambridge, UK) antibodies in PBS for overnight at 4°C. Then, sections washed in PBS (3×5 minutes) and incubated with respective secondary antibody in PBS for 2 hours at room temperature. DAPI solution (1 mg/mL of 4′,6-diamidino-2-phenylindole) incubation for nuclear DNA staining was performed for 30 seconds in the dark. The amount of GFP protein expression (green) and VEGF or troponin T were analyzed using a fluorescent microscope (Olympus Corporation, Japan) with higher magnifications (400×) and counted on five random fields for each section by a blinded investigator to experimental design. Data was analyzed by ImageJ software and presented as double positive cell count percent to cells positive for GFP.
Statistical analysis
Statistical analysis was done using SPSS software version 18 (IBM Incorporation, New York, USA). One-way analysis of variance (ANOVA) test was used for comparison of parameters between three groups and post-hoc MannWhitney U test was done for pairwise comparison of the groups. Mixed ANOVA with Bonferroni's adjustment was used to compare repeated measures of outcomes whenever required. The power of analysis was 80%, and the level of significance was 0.05.
Results
MSCs were defined with their spindle-form shape and adherent phenotype on culture plates during cell culture. Further characterization for confirming the identity of the cells demonstrated the positivity of the cell populations for CD44, CD73, CD90 and CD105 markers and negativity for CD34 and CD45 markers by flow cytometry technique (Figure 1 ). These as well as the potency of the cells to differentiate into the osteoblasts and adipocytes confirmed their identity as stem cells of mesenchymal type (Figure 2) .
After administration of the cells to the left ventricular myocardium, the cardiac function was measured on several occasions (before and four weeks after the cell administration) to see whether surgical treatment with hAMSCs can improve HF and/or prevent further loss of cardiac function. According to the results (Figure 3 ) echocardiographic measures demonstrated that both HF control and treatment groups had significant decrease in their EF and fractional shortening (P < 0.01) compared with the sham group. The findings are consistent with the characteristics of the dilated cardiomyopathy. However, significant differences between 2 groups, the cell therapy group compared with the untreated control group, were not observed in case of either EF and FS (P > 0.05). The calcified nodules appeared bright red in color after alizarin red staining of the osteocyte-differentiated hAMSCs (magnification ×100). myocardial infarction models. 10, [13] [14] [15] The cells have been isolated from various sources, including allogeneic and autologous donors and tissue origins such as bone marrow, adipose tissue and childbirth wastes. 12 MSCs from amniotic membrane have been tested for the treatment of acute myocardial infarction and HF related to coronary heart disease. However, most interventions have used acute myocardial ischemia model and investigated its effectiveness in the treatment of MI immediately or shortly after it. 10, 15 While results from these studies prove the preclinical efficacy of this type of the cells in the treatment of MI, it is not clear whether these cells are effective in the treatment of chronic MI associated with severe impairment of the heart function, advanced ventricular dilatation and HF. In the current study using rat models of HF related to chronic myocardial ischemia, we demonstrated that hAMSCs may not be effective in improving heart function or maintaining its function over the time. Indeed, treatment with hAMSCs did not show any effects on the HF and cardiac function parameters in the current study. Animals treated with this type of the cells were similar to untreated control groups in terms of ejection fraction and fractional shortening. Further histological examination demonstrated that the animals had a very similar amount of tissue fibrosis and myocardial collagen deposition. Contrary to our findings, Tsuji et al have found that xenograft of hAMSCs in subacute model of myocardial ischemia, when administered as early as two weeks following ischemia, in rats improved cardiac function. 32 hAMSCs are mostly effective in the early phases of the MI, mostly due to their immunomodulatory function, proangiogenic properties and cardiomyocyte differentiation. 32, 33 Indeed, these cells are mostly effective while early intervention could spare the cardiomyocytes from death due to metabolic disturbances and inflammatory response. 32 While in the late phases, the tissue has lost most of its cardiomyocytes and the myocardium is broadly replaced by nonfunctional fibrotic tissue, immune modulation and angiogenesis does not offer much benefit, for the improvement of the left ventricular ejection fraction. An evidence for substantiation of this hypothesis comes from a clinical trial
by Hare et al which tested the allogeneic and autologous MSCs in patients with chronic HF secondary to myocardial ischemia. 34 Their findings demonstrated that MSCs are well tolerated and are safe in these patients but do not improve patients' EF. Their findings are consistent with the results of the current study. Since in chronic ischemia and consequent HF the tissue loses a large fraction of its active cardiomyocytes, the reasonable regenerative approach is mostly dependent on the replacement of nonfunctional tissue with functional cardiomyocytes. While our study as well as previous studies have demonstrated the ability of these cells to differentiate into cells expressing cardiomyocyte markers, they do not acquire contractile activity required for mechanical activity of the myocardial tissue. 35 Shadrin et al demonstrated that these cells lack the potential to contraction despite their potential for the response to stimuli and capability in electromagnetic coupling with neighboring rat ventricular myocytes. Many more studies have evidenced the cardiomyogenic differentiation of MSCs, including hAMSCs, in vitro and in vivo. They have also been demonstrated to express molecules that are involved in the formation of gap junctions. 32, 34, 35 Although MSCs may show some molecular and phenotypic features of cardiac myocytes either through in vivo transdifferentiation or fusion with cardiomyocytes, they probably lack the potential stimuli response and contractility which are the final desired function expected from a treatment for failing myocardium. It is a cause for concern in cell therapy in chronic ischemic HF where a group of cardiomyocytes must work in concert and respond to stimuli to give rise to a functional myocardium. However, a limitation of the current study is to demonstrate the functional ability of the In sum, the study reveals that treatment of advanced chronic ischemic HF with hAMSCs does not offer much benefit in terms of myocardial function and tissue fibrosis. Cardiomyocyte like cells and vascular endothelial differentiation happens in a small fraction of cells and is not enough for functional recovery of cells. It appears that treatment of the myocardial ischemia in the early phases yields better outcomes.
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